Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Melanie C. Dispenza, Jennifer A. Regan & Bruce S. Bochner. (2017) Potential applications of Bruton’s tyrosine kinase inhibitors for the prevention of allergic reactions. Expert Review of Clinical Immunology 13:10, pages 921-923.
Read now
Read now
Parviz Kokhaei, Farhad Jadidi-Niaragh, Abdolreza Sotoodeh Jahromi, Anders Osterborg, Håkan Mellstedt & Mohammad Hojjat-Farsangi. (2016) Ibrutinib-A double-edge sword in cancer and autoimmune disorders. Journal of Drug Targeting 24:5, pages 373-385.
Read now
Read now
Racquel D. Innis-Shelton, Randall S. Davis, Lawrence Lamb & Shin Mineishi. (2015) Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. Leukemia & Lymphoma 56:6, pages 1626-1635.
Read now
Read now
Articles from other publishers (3)
Aleksandra Grela-Wojewoda, Renata Pacholczak-Madej, Agnieszka Adamczyk, Michał Korman & Mirosława Püsküllüoğlu. (2022) Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. International Journal of Molecular Sciences 23:5, pages 2815.
Crossref
Crossref
Nadezhda Viktorovna Kurkina, E.A. Repina & N.N. Mashnina. (2019) The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients. Clinical oncohematology 12:3, pages 278-281.
Crossref
Crossref
Caroline Smithson & Susan Schneider. (2015) Ibrutinib: A New Targeted Therapy for Hematologic Cancers. Clinical Journal of Oncology Nursing 19:3, pages E47-E51.
Crossref
Crossref